Project Grant R21NS142542
- Federal Grant Award Summary Yale University received a $583,646 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective March 20, 2026 through November 30, 2030. The award funds research investigating cilia disassembly and dysfunction as a shared pathogenic mechanism across multiple types of malformations of cortical development (MCDs),...
- Federal Grant Award Summary Yale University received a $471,402 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective July 1, 2025, through June 30, 2030. The award supports fundamental neuroscience research investigating the role of potassium channels in neuronal development and brain organization. Specifically, the research examines how the...
- Federal Grant Award Summary Yale University received a $1,270,816 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective May 9, 2025 through April 30, 2030. The grant supports research to decipher the gene regulatory networks (GRNs) that control the establishment, expansion, and maintenance of radial glia—the stem cells of the human...
- Federal Grant Award Summary Yale University received a $251,813 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective May 19, 2026 through April 30, 2028. The award funds the STROKE-CLOCK Study, a proteomics research initiative designed to identify and validate blood-based biomarker panels capable of estimating stroke onset time and...
- Federal Grant Award Summary Yale University received a $251,313 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded August 1, 2025, with completion targeted for July 31, 2027. The project aims to prospectively identify hypoxic-ischemic brain injury (HIBI) in cardiac arrest patients using portable low-field magnetic resonance imaging (MRI),...
- Federal Grant Award Summary Yale University received a $739,041 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded on March 20, 2026, with completion targeted for February 29, 2028. The research project investigates skin punch biopsy as a potential biomarker for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a rare acquired...
- Federal Grant Award Summary Yale University received a $272,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the 21st Century Cures Act - Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative (CFDA 93.372), effective September 30, 2025 through September 29, 2027. The research project develops and validates a novel virtual visual cliff behavioral task combined with head-mounted eye tracking technology to...
- Federal Grant Award Summary This $230,925 Project Grant, awarded August 1, 2025, by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), supports a five-year research initiative at Yale University examining central nervous system inflammation in aneurysmal subarachnoid hemorrhage (ASAH) patients. The project investigates whether the duration of the pro-inflammatory phase...
- Federal Project Grant Award Summary Yale University received a $722,338 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) on March 24, 2026. The award supports research extending through February 28, 2031, to develop automated, scalable clinical tools for predicting post-traumatic epilepsy (PTE) risk in traumatic brain injury (TBI) survivors. The...
- Federal Grant Award Summary The University of New Haven, Incorporated received a $131,360 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective September 1, 2025 through August 31, 2029. This award supports fundamental research to characterize and validate a glioblastoma stem cell (GSC)-associated long noncoding RNA (lncRNA) designated...
Yale University received a $462,151 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded May 19, 2026, with completion targeted for April 30, 2028. The award funds basic research investigating the genetic and molecular mechanisms underlying cerebral cavernous malformations (CCMs), a cerebrovascular disease characterized by vascular lesions in the central nervous system that cause seizures and hemorrhagic stroke. The research focuses specifically on CCM3 genetic subtype mutations, which produce the most aggressive form of the disease. The project deliverables include comprehensive genomic, transcriptomic, and single-cell chromatin accessibility analyses of CCM tissue specimens from donated brain samples harboring multiple lesions at different anatomical locations. Research outputs will advance understanding of the genomic, transcriptomic, and epigenetic landscape of CCMs and characterize the contribution of the local brain microenvironment to lesion formation. Through analysis of additional surgical specimens, the research team will identify unifying molecular principles of CCM pathogenesis, with findings intended to inform future therapeutic development for this rare neurological condition. The performance location is New Haven, Connecticut.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $462.2k | 5/20/26 |